Prostate Cancer Working Group 4 redefines trial frameworks in era of PSMA-PET and precision oncology
Andrew J. Armstrong, MD, MS, highlights updated recommendations from the Prostate Cancer Working Group 4.
Andrew J. Armstrong, MD, MSc
Advertisement
Articles by Andrew J. Armstrong, MD, MSc
At a median follow-up of 61.4 months, enzalutamide plus ADT continued to show an improvement in OS vs ADT alone.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves capivasertib plus abiraterone and prednisone for PTEN-deficient mHSPC
2
Dean Elterman, MD, highlights efficacy and safety data on the Zenflow Prostatic Spring
3
Toni Choueiri, MD, reacts to FDA approval of adjuvant belzutifan with pembrolizumab for ccRCC
4
FDA approves adjuvant belzutifan with pembrolizumab for ccRCC
5